RETR(Osteomyelitis)

Study Overview
=================
Brief Summary
-----------------
This is a retrospective study describing the management of osteomyelitis in a referece center, with success and failures.

Detailed Description
-----------------
Chronic osteomyelitis is a serious osteoarticular infection that most often occurs in the long bones (tibia, femur, humerus), responsible for significant morbidity with the risk of fracture and amputation. It is caused by the presence of bacteria in the bone marrow, sometimes responsible for an intraosseous abscess. Chronic osteomyelitis can have a hematogenous or more often exogenous origin, after trauma or surgery. Despite the progress made in both antibiotics and surgical treatment, the probability of failure of this treatment (infectious recurrence) is of the order of 20%, and has unfortunately remained stable for more than 20 years. An innovative treatment, Cerament-G (BONESUPPORT AB Laboratory, Sweden), a synthetic bone substitute composed of hydroxyapatite, calcium sulphate, and gentamicin (CE marking), fills the dead space which is formed during surgery, prevents this cavity filled with blood from becoming infected, and promotes the regeneration of the bone within this space, limiting the risk of fracture in the medium and long term. It also locally delivers very high doses of gentamicin for several weeks.

Official Title
-----------------
RETR(Osteomyelitis)

Conditions
-----------------
Osteomyelitis

Intervention / Treatment
-----------------
* Other: patients having had an osteomyelitis since 2017


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who presented with osteomyelitis between 2017 and 2021 Exclusion Criteria: Patients who objected to participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients having had an osteomyelitis since 2017<br> | Other: patients having had an osteomyelitis since 2017<br>* description of osteomyelitis and their management<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of osteomyelitis in BJI | proportion of patients having had an osteomyelitis | between 2017 and 2021 | 
| site of osteomyelitis | localisation | between 2017 and 2021 | 
| bone defect size | dimension of the bone defect size | between 2017 and 2021 | 
| type of osteomyelitis | hematogenous or after a trauma or after a surgery | between 2017 and 2021 | 
| rate of bacteria involved in osteomyelitis | description of bacteria responsible for osteomyelitis | between 2017 and 2021 | 
| Description of patients | comorbidities, age | between 2017 and 2021 | 
| Description of the follow up of the patients | duration of the follow up of patients | between 2017 and 2021 | 
| description of patients : medical treatment | description and duration of antibiotics | between 2017 and 2021 | 
| Description of patients : surgical treatment | description of surgery performed | between 2017 and 2021 | 
| rate of patient treated with CERAMENT | proportion of patients having had CERAMENT | between 2017 and 2021 | 
| rate of treatment failure | treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | between 2017 and 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hematogenous, bone substitute